N-(3-甲氧基苯基)-4-甲基苯甲酰胺 | 101078-45-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-甲氧基苯基)-4-甲基苯甲酰胺
• 中文别名: N-(3-甲基苯基)-4-甲基苯甲酰胺
• 英文名称: N-(3-methoxyphenyl)-4-methylbenzamide
• CAS: 101078-45-9
• 化学式: C₁₅H₁₅NO₂
• mdl: MFCD00088042
• 分子量: 241.29
• InChiKey: LHGUCPJOIROFJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-甲氧基苯基)-4-甲基苯甲酰胺 在 劳森试剂 、 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 、 氢溴酸 、 potassium hexacyanoferrate(III) 作用下， 以 四氯化碳 、 水 、 甲苯 为溶剂， 反应 25.25h， 生成 [2-[4-(Diethoxyphosphorylmethyl)phenyl]-1,3-benzothiazol-7-yl] acetate
  参考文献：
  名称：

  Organic phosphorus compounds. 1. 4-(Benzothiazol-2-yl)benzylphosphonate as potent calcium antagonistic vasodilator

  摘要：

  A series of 4-(benzothiazol-2-yl)benzylphosphonic acid dialkyl ester derivatives were synthesized and evaluated for coronary vasodilatory activity by Langendorff's method in the isolated guinea pig heart. Many of the phosphonic acid dialkyl esters exhibited vasodilatory activity and calcium antagonism comparable with those of diltiazem hydrochloride, whereas phosphonic acid 1b and its nonphosphonated precursor 7a were inactive. These results indicate the necessity of the diethoxyphosphinyl moiety for vasodilatory activity. Substitution of the benzothiazole ring with a variety of substituents did not significantly enhance the activity of the unsubstituted compound. Compound 10b (KB-944) was chosen for detailed pharmacological evaluation.

  DOI：

  10.1021/jm00155a037
• 作为产物：
  描述：

  对甲基苯甲酰氯 在 lithium selenide 作用下， 以 四氢呋喃 为溶剂， 反应 16.5h， 生成 N-(3-甲氧基苯基)-4-甲基苯甲酰胺
  参考文献：
  名称：

  一锅式合成酰胺和衍生物的无痕硒代羧酸盐

  摘要：

  我们最近报道了使用硒代羧酸盐作为无痕迹试剂的一锅法合成糖基酰胺的方法。在本文中，我们提出硒羧酸叠氮化物反应在更宽范围的底物（包括杂环系统和脂肪酸）上形成酰胺键的进一步应用。事实证明，该方法对于合成伯酰胺和仲酰胺，磺酰胺，酰亚胺，磷酰胺以及氨基甲酸酯非常有效。

  DOI：

  10.1016/j.tet.2020.131834

文献信息

• Triflic anhydride mediated synthesis of 3,4-dihydroquinazolines: a three-component one-pot tandem procedure
  作者：Christina L. Magyar、Tyler J. Wall、Steven B. Davies、Molly V. Campbell、Haven A. Barna、Sydney R. Smith、Christopher J. Savich、R. Adam Mosey

  DOI：10.1039/c9ob01596e

  日期：——

  A one-pot three-component tandem reaction involving a key Pictet-Spengler-like annulation step has been developed, providing an efficient method for the synthesis of 3,4-dihydroquinazolines in moderate to good yields from amides, aldehydes, and amines. The multicomponent triflic anhydride mediated reaction tolerates the installation of numerous functional groups, affording extensive diversity about

  已经开发了涉及关键的Pictet-Spengler样环化步骤的一锅三组分串联反应，为从酰胺，醛和胺中到高收率的合成3,4-二氢喹唑啉提供了一种有效的方法。多组分三氟甲磺酸酐介导的反应可耐受许多官能团的安装，从而为杂环支架提供了广泛的多样性。
• Stable and Reusable Binaphthyl‐Supported Palladium Catalyst for Aminocarbonylation of Aryl Iodides
  作者：Nidhi Sharma、Govindasamy Sekar

  DOI：10.1002/adsc.201500642

  日期：2016.1.21

  A binaphthyl‐supported Pd nanoparticles (Pd‐BNP)‐catalyzed aminocarbonylation of aryl iodides in the presence of carbon monoxide and amines for the synthesis of amides has been developed. This methodology provides an efficient route for the synthesis of a COX‐2 enzyme inhibitor having anti‐inflammatory activity.

  已经开发了在二氧化碳和胺存在下，联萘负载的Pd纳米颗粒（Pd-BNP）催化的芳基碘的氨基羰基化反应，用于合成酰胺。这种方法为合成具有抗炎活性的COX-2酶抑制剂提供了一条有效途径。
• BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS
  申请人：Galley Guido

  公开号：US20090036420A1

  公开（公告）日：2009-02-05

  The present invention relates to methods of treating CNS disorders with a compound of formula I wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof.

  本发明涉及使用式I中的化合物治疗中枢神经系统疾病的方法，其中X、R1、R2、R3、R4、R5、R6、R7和R8如说明书中所定义，并且包括药学上可接受的酸盐。
• YOSHINO, KOHICHIRO;KOHNO, TOSHIHIKO;UNO, TOSHIO;TOMINORI, MORITA;TSUKAMOT+, J. MED. CHEM., 1986, 29, N 5, 820-825
  作者：YOSHINO, KOHICHIRO、KOHNO, TOSHIHIKO、UNO, TOSHIO、TOMINORI, MORITA、TSUKAMOT+

  DOI：——

  日期：——
• [EN] THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZAMIDE POUR LE TRAITEMENT DE TROUBLES DU SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009016088A1

  公开（公告）日：2009-02-05

  The present invention relates to the use of a compound of formula (I), wherein R or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of CNS disorders selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress- related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.